KIT c.756G>T ;(p.Q252H)

Variant ID: 4-55565932-G-T

NM_000222.2(KIT):c.756G>T;(p.Q252H)

This variant was identified in 23 publications

View GRCh38 version.




Publications:


Systematic review and meta-analysis of genomic alterations in acral melanoma.

Pigment Cell & Melanoma Research
Broit, Natasa N; Johansson, Peter A PA; Rodgers, Chloe B CB; Walpole, Sebastian T ST; Hayward, Nicholas K NK; Pritchard, Antonia L AL
Publication Date: 2022-05

Variant appearance in text: KIT: Q252H
PubMed Link: 35229492
Variant Present in the following documents:
  • PCMR-35-369-s003.xlsx, sheet 12
View BVdb publication page



Phosphorylated WNK kinase networks in recoded bacteria recapitulate physiological function.

Cell Reports
Schiapparelli, Paula P; Pirman, Natasha L NL; Mohler, Kyle K; Miranda-Herrera, Pierre A PA; Zarco, Natanael N; Kilic, Onur O; Miller, Chad C; Shah, Sagar R SR; Rogulina, Svetlana S; Hungerford, William W; Abriola, Laura L; Hoyer, Denton D; Turk, Benjamin E BE; Guerrero-Cázares, Hugo H; Isaacs, Farren J FJ; Quiñones-Hinojosa, Alfredo A; Levchenko, Andre A; Rinehart, Jesse J
Publication Date: 2021-07-20

Variant appearance in text: KIT: Q252H
PubMed Link: 34289367
Variant Present in the following documents:
  • NIHMS1726840-supplement-2.xlsx, sheet 1
View BVdb publication page



Application of a small molecule inhibitor screen approach to identify CXCR4 downstream signaling pathways that promote a mesenchymal and fulvestrant-resistant phenotype in breast cancer cells.

Oncology Letters
Matossian, Margarite D MD; Elliott, Steven S; Rhodes, Lyndsay V LV; Martin, Elizabeth C EC; Hoang, Van T VT; Burks, Hope E HE; Zuercher, William J WJ; Drewry, David H DH; Collins-Burow, Bridgette M BM; Burow, Matthew E ME
Publication Date: 2021-05

Variant appearance in text: KIT: Q252H
PubMed Link: 33777204
Variant Present in the following documents:
  • Main text
View BVdb publication page



Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy.

Journal Of Hematology & Oncology
Rossari, Federico F; Minutolo, Filippo F; Orciuolo, Enrico E
Publication Date: 2018-06-20

Variant appearance in text: CD117: Q252H
PubMed Link: 29925402
Variant Present in the following documents:
  • Main text
  • 13045_2018_Article_624.pdf
View BVdb publication page



Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.

Oncotargets And Therapy
Pinilla-Ibarz, Javier J; Sweet, Kendra L KL; Corrales-Yepez, Gabriela M GM; Komrokji, Rami S RS
Publication Date: 2016

Variant appearance in text: KIT: Q252H
PubMed Link: 27570458
Variant Present in the following documents:
  • Main text
View BVdb publication page



Second-generation TKIs: which and when?

Leukemia Supplements
Saglio, G G
Publication Date: 2012-08

Variant appearance in text: KIT: Q252H
PubMed Link: 27175246
Variant Present in the following documents:
  • Main text
View BVdb publication page



A Semantic Web-based System for Mining Genetic Mutations in Cancer Clinical Trials.

Amia Joint Summits On Translational Science Proceedings. Amia Joint Summits On Translational Science
Priya, Sambhawa S; Jiang, Guoqian G; Dasari, Surendra S; Zimmermann, Michael T MT; Wang, Chen C; Heflin, Jeff J; Chute, Christopher G CG
Publication Date: 2015

Variant appearance in text: KIT: Q252H
PubMed Link: 26306257
Variant Present in the following documents:
  • Main text
  • 2092277.pdf
View BVdb publication page



Secondary mutations as mediators of resistance to targeted therapy in leukemia.

Blood
Daver, Naval N; Cortes, Jorge J; Ravandi, Farhad F; Patel, Keyur P KP; Burger, Jan A JA; Konopleva, Marina M; Kantarjian, Hagop H
Publication Date: 2015-05-21

Variant appearance in text: KIT: Q252H
PubMed Link: 25795921
Variant Present in the following documents:
  • Main text
View BVdb publication page



Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study.

Plos One
Tanneeru, Karunakar K; Guruprasad, Lalitha L
Publication Date: 2013

Variant appearance in text: KIT: Q252H
PubMed Link: 24236021
Variant Present in the following documents:
  • pone.0078556.pdf
View BVdb publication page



Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.

Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology
Li, Tianhong T; Kung, Hsing-Jien HJ; Mack, Philip C PC; Gandara, David R DR
Publication Date: 2013-03-10

Variant appearance in text: KIT: Q252H
PubMed Link: 23401433
Variant Present in the following documents:
  • Main text
View BVdb publication page



Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia.

Revista Brasileira De Hematologia E Hemoterapia
Bitencourt, Roberta R; Zalcberg, Ilana I; Louro, Iúri Drumond ID
Publication Date: 2011

Variant appearance in text: KIT: Q252H
PubMed Link: 23049365
Variant Present in the following documents:
  • rbhh-33-470.pdf
View BVdb publication page



The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.

Cancer Research
Hantschel, Oliver O; Grebien, Florian F; Superti-Furga, Giulio G
Publication Date: 2012-10-01

Variant appearance in text: KIT: Q252H
PubMed Link: 23002203
Variant Present in the following documents:
  • Main text
View BVdb publication page



Oncogene Mutation Survey in MPNST Cell Lines Enhances the Dominant Role of Hyperactive Ras in NF1 Associated Pro-Survival and Malignancy.

Translational Oncogenomics
Sun, Daochun D; Tainsky, Michael A MA; Haddad, Ramsi R
Publication Date: 2012

Variant appearance in text: KIT: Q252H
PubMed Link: 22346343
Variant Present in the following documents:
  • Main text
View BVdb publication page



Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics.

The Journal Of Biological Chemistry
Liu, Qingsong Q; Kirubakaran, Sivapriya S; Hur, Wooyoung W; Niepel, Mario M; Westover, Kenneth K; Thoreen, Carson C CC; Wang, Jinhua J; Ni, Jing J; Patricelli, Matthew P MP; Vogel, Kurt K; Riddle, Steve S; Waller, David L DL; Traynor, Ryan R; Sanda, Takaomi T; Zhao, Zheng Z; Kang, Seong A SA; Zhao, Jean J; Look, A Thomas AT; Sorger, Peter K PK; Sabatini, David M DM; Gray, Nathanael S NS
Publication Date: 2012-03-23

Variant appearance in text: KIT: Q252H
PubMed Link: 22223645
Variant Present in the following documents:
  • Main text
View BVdb publication page



Evolution of therapies for chronic myelogenous leukemia.

Cancer Journal (Sudbury, Mass.)
Santos, Fabio P S FP; Kantarjian, Hagop H; Quintás-Cardama, Alfonso A; Cortes, Jorge J
Publication Date: 2011

Variant appearance in text: KIT: Q252H
PubMed Link: 22157290
Variant Present in the following documents:
  • Main text
View BVdb publication page



Chronic myeloid leukemia: mechanisms of resistance and treatment.

Hematology/Oncology Clinics Of North America
Jabbour, Elias E; Parikh, Sameer A SA; Kantarjian, Hagop H; Cortes, Jorge J
Publication Date: 2011-10

Variant appearance in text: C-Kit: Q252H
PubMed Link: 22054730
Variant Present in the following documents:
  • Main text
View BVdb publication page



Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.

Clinical Lymphoma, Myeloma & Leukemia
Cornelison, A Megan AM; Kantarjian, Hagop H; Cortes, Jorge J; Jabbour, Elias E
Publication Date: 2011-06

Variant appearance in text: KIT: Q252H
PubMed Link: 22035738
Variant Present in the following documents:
  • Main text
View BVdb publication page



The energy landscape analysis of cancer mutations in protein kinases.

Plos One
Dixit, Anshuman A; Verkhivker, Gennady M GM
Publication Date: 2011

Variant appearance in text: KIT: Q252H
PubMed Link: 21998754
Variant Present in the following documents:
  • Main text
View BVdb publication page



Mechanisms of drug resistance in kinases.

Expert Opinion On Investigational Drugs
Barouch-Bentov, Rina R; Sauer, Karsten K
Publication Date: 2011-02

Variant appearance in text: KIT: Q252H
PubMed Link: 21235428
Variant Present in the following documents:
  • Main text
View BVdb publication page



Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.

Blood
Weisberg, Ellen E; Choi, Hwan Geun HG; Ray, Arghya A; Barrett, Rosemary R; Zhang, Jianming J; Sim, Taebo T; Zhou, Wenjun W; Seeliger, Markus M; Cameron, Michael M; Azam, Mohammed M; Fletcher, Jonathan A JA; Debiec-Rychter, Maria M; Mayeda, Mark M; Moreno, Daisy D; Kung, Andrew L AL; Janne, Pasi Antero PA; Khosravi-Far, Roya R; Melo, Junia V JV; Manley, Paul W PW; Adamia, Sophia S; Wu, Catherine C; Gray, Nathanael N; Griffin, James D JD
Publication Date: 2010-05-27

Variant appearance in text: KIT: Q252H
PubMed Link: 20299508
Variant Present in the following documents:
  • Main text
View BVdb publication page



Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.

Leukemia & Lymphoma
Santos, Fabio P S FP; Ravandi, Farhad F
Publication Date: 2009-12

Variant appearance in text: C-Kit: Q252H
PubMed Link: 20017607
Variant Present in the following documents:
  • Main text
View BVdb publication page



AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.

British Journal Of Cancer
Weisberg, E E; Manley, P P; Mestan, J J; Cowan-Jacob, S S; Ray, A A; Griffin, J D JD
Publication Date: 2006-06-19

Variant appearance in text: KIT: Q252H
PubMed Link: 16721371
Variant Present in the following documents:
  • 94-6603170a.pdf
View BVdb publication page



Cancer treatment with kinase inhibitors: what have we learnt from imatinib?

British Journal Of Cancer
Ross, D M DM; Hughes, T P TP
Publication Date: 2004-01-12

Variant appearance in text: KIT: Q252H
PubMed Link: 14710199
Variant Present in the following documents:
  • Main text
View BVdb publication page